Kali-Extracts and Puration Announce First Shipment Of Hemp-Derived CBD Infused Private Label Water For Pharmaceutical Client
December 13 2018 - 01:00PM
InvestorsHub NewsWire
Kali-Extracts and Puration Announce
First Shipment Of Hemp-Derived CBD Infused Private Label Water For
Pharmaceutical Client
Dallas, TX -- December 13, 2018 --
InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc.
dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) and Puration, Inc. (USOTC:
PURA) (“PURA”) today announced shipping the first private
labeled, hemp-derived CBD infused, high alkaline water to Generex
Biotechnology Corporation (OTCQB:
GNBT) in conjunction with a previously announced agreement to produce $1 million of CBD infused
water for Generex. PURA is producing the CBD
infused water for Generex and PURA has in turn engaged KALY in a
$300,000 contract to produce the CBD extract specific to the
requirements of Generex.
Kali-Extracts recently acquired a patented
cannabis extraction process, that comes with a substantial volume
of associated clinical research. Since the acquisition of the
patented cannabis extraction process, Kali-Extracts and Puration,
with two other partners, have together formed a joint venture
company (JV) titled US Cannabis Health. The purpose of the JV
is to pursue partnerships with pharmaceutical companies to produce
cannabis extract pharmaceutical
applications.
For
more information visit:
www.kali-extracts.com
and
www.purationinc.com
Disclaimer/Safe
Harbor:
This news release
contains forward-looking statements within the meaning of the
Securities Litigation Reform Act. The statements reflect the
Company's current views with respect to future events that involve
risks and uncertainties. Among others, these risks include the
expectation that any of the companies mentioned herein will achieve
significant sales, the failure to meet schedule or performance
requirements of the companies' contracts, the companies' liquidity
position, the companies' ability to obtain new contracts, the
emergence of competitors with greater financial resources and the
impact of competitive pricing. In the light of these uncertainties,
the forward-looking events referred to in this release might not
occur. These statements have not been evaluated by the Food and
Drug Administration. These products are not intended to diagnose,
treat, cure, or prevent any
disease.
Puration,
Inc.
Contact:
Puration,
Inc.
Brian
Shibley,
info@aciconglomerated.com
(800)
861-1350
Kali, Inc.
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Mar 2023 to Mar 2024